19 results
6-K
EX-99.1
SNY
Sanofi
25 Apr 24
Sales growth of 6.7% at CER and business EPS(1) of €1.78
10:49am
in scope 1&2 greenhouse gas emissions (CO2 equivalent) by 2030 (cumulative vs 2019 baseline) to contribute to carbon neutrality by 2030 and net zero
6-K
EX-99.1
SNY
Sanofi
1 Feb 24
Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
9:45am
is grounded in two focus areas:
Reducing the impact of its activities and products on the environment: between 2019 and 2023 we reduced our scope 1 and 2 … % reduction in scope 1&2 greenhouse gas emissions (CO2 equivalent) by 2030 (cumulative vs 2019 baseline) to contribute to carbon neutrality by 2030 and net
6-K
EX-99.1
SNY
Sanofi
27 Oct 23
Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results
12:39pm
footprint
(CO2 emissions)
55% reduction in scope 1&2 greenhouse gas emissions (CO2 equivalent) by 2030 (cumulative vs 2019 baseline) to contribute to carbon
6-K
EX-99.1
SNY
Sanofi
28 Jul 23
Solid Q2 performance and strong pipeline momentum
3:35pm
)
Scope 1 & 2 GHG emissions reduction
Q1 2023
Q2 2023
GHG reduction vs 2019 %
Renewable electricity
Q1 2023
Q2 2023
% electricity consumption from
6-K
EX-99.2
SNY
Sanofi
28 Jul 23
Condensed Half-year Consolidated Financial Statements
7:00am
to achieve Net Zero emissions across all operations (scope 1 & 2) and the entire value chain (scope 3) by 2045. This target has been vetted by SBTi as well
6-K
EX-99.1
d15w8y2l f8k8p9wob
27 Apr 23
Strong Q1 growth driven by Specialty Care, Vaccines and CHC
11:39am
6-K
EX-99.1
pb4hdechswg og4kcd
28 Oct 22
Continued strong growth in Q3 with key regulatory milestones achieved
11:16am
6-K
EX-99.1
xgz 1vasr7ben1cnf
28 Jul 22
Strong execution in Q2 drives full-year 2022 guidance upgrade and delivers rich R&D news flow in Immunology and Rare Disease
10:12am
6-K
EX-99.2
wixvtuwzsmbd7eu86
28 Jul 22
Condensed Half-year Consolidated Financial Statements
6:17am
6-K
EX-99.1
07r6gasam9vjet
28 Apr 22
Sanofi continues to deliver strong business EPS(1) growth driven by higher sales and improved margins in Q1
12:16pm
6-K
EX-99.1
5fjx0fvowi0ce2ibt
4 Apr 22
Distribution of Shares of Euroapi
11:21am
6-K
EX-99.1
hz94yho
28 Oct 21
Q3 2021 sales grew double digit to €10.4 billion (up 10.1%) due to strong growth from Dupixent®, Vaccines and CHC
11:19am
6-K
EX-99.2
t1dkxn yjzj
11 Dec 20
Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly
3:25pm
- Prev
- 1
- Next